Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 20, 2016

Dr. Reddy’s Promius launches Zembrace SymTouch in US to treat acute migraine

Dr. Reddy’s Laboratories subsidiary Promius Pharma has launched Zembrace SymTouch in the US to treat patients with acute migraine.

Dr. Reddy’s Laboratories subsidiary Promius Pharma has launched Zembrace SymTouch in the US to treat patients with acute migraine.

Migraine is a primary headache disorder characterised by recurrent headaches that are moderate to severe. Its associated symptoms include nausea, vomiting, and sensitivity to light, sound, or smell.

The headaches affect one half of the head and are pulsating in nature, and last from two to 72 hours.

Promius’ Zembrace SymTouch is a prefilled, low-dose, ready-to-use, two-step autoinjector that contains 3mg of sumatriptan, a selective 5-HT1B/ID receptor agonist.

"This 3mg, easy to-use subcutaneous injection of sumatriptan may be desired by many migraine patients who need a medication that can rapidly treat migraine attacks."

This prescription medicine is used to treat acute migraine headaches with or without aura in adults who have been diagnosed with a migraine. It is not used to prevent or decrease the number of migraines.

National Headache Foundation associate executive chairman Roger Cady said: "Zembrace SymTouch is a welcome addition to the toolkit for acute treatment of migraine.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

"This 3mg, easy to-use subcutaneous injection of sumatriptan may be desired by many migraine patients who need a medication that can rapidly treat migraine attacks.

"Also, the 3mg dose allows for up to four doses of Zembrace SymTouch in a 24-hour period, therefore allowing dosing flexibility for patients."

The launch comes on the heels of approval from the US Food and Drug Administration (FDA) in January this year.

Zembrace SymTouch is not recommended for people with risk factors for heart disease unless a heart exam is done and shows no problem.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU